Eric Walker added Ceftolozane/tazobactam: New treatment option for severe infections, but no proof of superiority to Ceftolozane-tazobactam

Eric Walker added Ceftolozane/Tazobactam Effective in Treating Some ESBL-E Infections to Ceftolozane-tazobactam and Extended spectrum beta-lactamases (ESBL)

Eric Walker added Consider the MIC: Treating Respiratory Infections Caused by Pseudomonas aeruginosa With Ceftolozane/Tazobactam to Drug-resistant Pseudomonas aeruginosa and Ceftolozane-tazobactam

Eric Walker added Continuous Infusion Ceftolozane/Tazobactam Could Be an Option for Treating MDR Infections to Ceftolozane-tazobactam

Eric Walker added Yoav Golan, MD, on the Recent Approval of Ceftolozane/Tazobactam for HABP/VABP to Ceftolozane-tazobactam

Eric Walker added Resistance to last resort drug arose in patient over 3 weeks to a number of topics

Eric Walker added Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens to a number of topics

Eric Walker added Ceftolozane/Tazobactam Deemed Safe, Effective Against Drug-Resistant P aeruginosa to Ceftolozane-tazobactam

Eric Walker added Comparison of Antibiotic Activity in Complicated UTI From Gram-Negative Bacteria - Infectious Disease Advisor to a number of topics

Eric Walker added Ceftolozane/tazobactam potential new treatment for serious nosocomial pneumonia: Lancet to Ceftolozane-tazobactam

Eric Walker added Stewardship / Resistance Scan for Sep 26, 2019 | CIDRAP to Ceftolozane-tazobactam, Extensively drug-resistant (XDR) typhoid and Meropenem

Eric Walker added Yoav Golan, MD, on the Recent Approval of Ceftolozane/Tazobactam for HABP/VABP to Ceftolozane-tazobactam

Eric Walker added FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) to Ceftolozane-tazobactam

Eric Walker added FDA Approves Ceftolozane/Tazobactam for HABP/VABP to Ceftolozane-tazobactam, Meropenem and Multidrug-resistant (MDR) Pseudomonas aeruginosa

Eric Walker added a number of topics and a number of links to Specific antibiotics, and added Specific antibiotics to Antibiotic agents

Eric Walker added a number of topics and a number of links to New and investigational antibiotics, and added New and investigational antibiotics to Specific antibiotics and New and investigational drugs

Eric Walker added 2019-09 Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial and a number of links to Ceftolozane-tazobactam, and added Ceftolozane-tazobactam to New and investigational antibiotics, Tazobactam and Specific antibiotics

Eric Walker added Ceftolozane-tazobactam and Piperacillin-tazobactam to Tazobactam, and added Tazobactam to Sulfone β-lactamase inhibitors

Eric Walker added Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial to Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial, and added Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial to Ceftolozane-tazobactam